San Francisco-based cognitive assessment app maker Savonix announced the launch of its  Japanese website, Savnonix.jp. The website explains the science behind Savonix’s brain health platform. 

It highlights ways the company can provide cognitive health and data insights to support people and companies in Japan to monitor brain health, understand risk factors for developing dementia and take steps to reduce the risk of getting dementia.

WHY IT MATTERS

More than 4.6 million people in Japan suffer from some form of dementia, with the total expected to soar to about 7.3 million people by 2025. The numbers underscore the importance of cognitive testing for early detection of impairment.

Savnonix says its flagship product, Savonix Mobile, which was first launched in 2016 and is available in the app store, provides cognitive tests and lifestyle risk assessments for dementia that can be taken on any mobile device. The app is available in Japan through the company’s partnerships with Fujitsu Connected Technologies Limited and Mitani Sangyo companies.Co, Ltd.

THE LARGER TREND 

In April 2019, Savonix raised $9.6 million in what the company is calling an extension of its 2017 $5.1 million Series A round, MobiHealthNews reported. Their investors suggested that the latest funding round is focused on an expansion into Asian markets, particularly Japan, which has unique needs around dementia and Alzheimer's.

ON THE RECORD

“I’m excited that the Savonix website is now available in Japan. Japan faces the world’s highest rate of dementia in a super aging society and we are thrilled to help the people of Japan with resources to better understand dementia and to monitor their brain health to reduce risk,” said Dr Mylea Charvat, Founder, and CEO of Savonix.

“The website also provides another avenue for us to stress the importance of taking cognitive assessments regularly and living a healthy lifestyle to prevent dementia.”